Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2014

View Archived Issues

Genzyme establishes collaboration to develop gene therapy for Leber's congenital amaurosis

Baxter and Merrimack sign ex-U.S. license agreement for MM-398

Celldex Therapeutics begins pilot study of CDX-301

Alnylam begins study examining the prevalence of TTR mutations in cardiac amyloidosis

Diaxonhit completes enrollment in validation study of BJI InoPlex

Repros reports data from second pivotal study of Androxal for secondary hypogonadism

Additional approval obtained for pediatric administration of Vfend in Japan

Pfizer completes InnoPharma acquisition

MicroBiome's NM-505 may improve tolerability of metformin in type 2 diabetes

Bayer presents data from 11-year follow-up of the BENEFIT trials

ARN-2508, an orally available therapeutic for the potential treatment of pain and inflammation

Researchers from Visterra present a novel humanized antibody against dengue virus

SostAb shows promise for fracture healing in animal models of type 1 diabetes

Merck & Co. patents novel LRRK2 inhibitors

Roche divulges new agents for HCV infection

Novel anticancer agents disclosed by TD2

EMA committee recommends approval of Rezolsta, announces darunavir label extensions

New NS5B inhibitors presented by Bristol-Myers Squibb

Influenza drug Avigan administered to patient with Ebola

Roche presents new BTK inhibitors

Lymphoseek recommended by CHMP for sentinel lymph node detection

Bristol-Myers Squibb provides milestone update for Opdivo

FDA grants multiple orphan drug designations to aldoxorubicin

NeuroGenetic cleared to begin phase I trials of NGP-555 for Alzheimer's disease

FDA awards orphan drug designation to Insys Therapeutics' cannabidiol for glioma

Daiichi Sankyo and Ambit Biosciences enter merger agreement

Pegylated liposomal mitomycin-C lipid-based prodrug shows promise in phase I trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...